These patients typically exhibited low expression of programmed cell death protein 1 (PD-1) and had a low burden of tumor mutation.13,14 Therefore, upon progression after first-line chemotherapy, the options for second- and subsequent-line treatments are narrow, representing unmet medical needs in this setting. The gene discussed is PDCD1; the disease is neoplasm.